POINT Biopharma Global OverviewLatest ebit for PNT: $97M, below the Healthcare sector average of $99B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2023
Trailing 12 months ending Sep 30, 2023
As of the most recent data (September 2023), PNT shows a EBIT of $97M. That is below the Healthcare sector average of $99B. Scroll down for historical charts and peer comparison views.
The Healthcare sector average EBIT is about $99B. POINT Biopharma Global is at $97M, which is lower that average. That is roughly 99.9% below the sector mean. Use the comparison chart on this page to see how PNT stacks up against individual peers as well.
Tracking PNT's ebit over time shows whether POINT Biopharma Global is scaling, shrinking, or reshaping that part of the business. The current reading is $97M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has POINT Biopharma Global's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $97M) with ownership activity and broader fundamentals.
The Healthcare average EBIT is about $99B, while PNT is at $97M. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
